Author

Wu Zhang

Observed name: W. Zhang

ORCID: 0000-0002-2629-5455

Observed ORCID: 0000-0002-2629-5455

OpenAlex ID: A5080912482

Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al. · Clinical Cancer Research · 20

Supplementary Figure S2 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al.

Supplementary Figure S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al.

Supplementary Table S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al.

Supplementary Methods S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al.

Supplementary Figure S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al.

Supplementary Table S2 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al.

Data from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al.

Supplementary Figure S3 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al.

Data from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al.

Supplementary Table S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al.

PO-442 Ex vivo prostate cancer culture system recapitulates in vivo response to androgen antagonist

2018 · W. Zhang, W. Van Weerden, et al. · ESMO Open

2553 Development of a small molecule for treatment of castration resistant prostate cancer via androgen receptor and IL6/STAT3 pathways

2015 · Y. Hua, W. Azeem, et al. · European Journal of Cancer

Works count: 13

Citation count: 20

H-index: 1

I10-index: 1